Thomas Mathers
Directeur Général chez Déclion Pharmaceuticals, Inc.
Postes actifs de Thomas Mathers
Sociétés | Poste | Début | Fin |
---|---|---|---|
Déclion Pharmaceuticals, Inc. | Directeur Général | 01/01/2011 | - |
Président | 01/01/2011 | - | |
Fondateur | 01/01/2011 | - | |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | 10/04/2018 | - |
Allievex Corp.
Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Directeur/Membre du Conseil | 01/04/2018 | - |
Directeur Général | 01/04/2018 | - | |
Fondateur | 01/04/2018 | - | |
President | 01/04/2018 | - | |
AM Pappas Life Science Ventures V | Corporate Officer/Principal | 01/02/2018 | - |
Butler University | Directeur/Membre du Conseil | - | - |
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Directeur/Membre du Conseil | - | - |
Independent Dir/Board Member | - | - | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Thomas Mathers
Anciens postes connus de Thomas Mathers
Sociétés | Poste | Début | Fin |
---|---|---|---|
COLUCID PHARMACEUTICALS INC | Directeur/Membre du Conseil | 01/06/2011 | 01/03/2017 |
Directeur Général | 01/06/2011 | 01/07/2017 | |
President | 01/06/2011 | 01/03/2017 | |
CureFAktor Pharmaceuticals LLC | Directeur/Membre du Conseil | 01/05/2012 | 01/12/2014 |
Corporate Officer/Principal | 01/05/2012 | 01/12/2014 | |
░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░ ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░░ ░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░ ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formation de Thomas Mathers
US Military Academy | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 19 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 9 |
Corporate Officer/Principal | 7 |
Chief Executive Officer | 5 |
Sectorielle
Health Technology | 9 |
Finance | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
PFIZER, INC. | Health Technology |
Entreprise privées | 16 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Cary Street Partners LLC
Cary Street Partners LLC Investment ManagersFinance Cary Street Partners LLC provides wealth management and investment banking services. It offers research & portfolio advisory, financial planning, insurance & estate planning and investment banking services. The company was founded by Mark M. Gambill and Thomas H. Tullidge Jr. in 2002 and is headquartered in Richmond, VA. | Finance |
CoLucid Pharmaceuticals, Inc.
CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Snowden Pencer, Inc.
Snowden Pencer, Inc. Medical SpecialtiesHealth Technology Snowden Pencer, Inc. is a company that manufactures medical supplies. The company is based in Tucker, GA. Snowden Pencer was acquired by Cardinal Health, Inc. on March 05, 2004. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
The United States Army (District of Columbia) | Government |
Cell Based Delivery, Inc. | |
Déclion Pharmaceuticals, Inc. | |
CureFAktor Pharmaceuticals LLC | |
Allievex Corp.
Allievex Corp. Pharmaceuticals: OtherHealth Technology Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA. | Health Technology |
Lifesci Acquisition II Corp.
Lifesci Acquisition II Corp. Financial ConglomeratesFinance LifeSci Acquisition II Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on December 18, 2019 and is headquartered in New York, NY. | Finance |
AM Pappas Life Science Ventures V | |
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Health Technology |
- Bourse
- Insiders
- Thomas Mathers
- Expérience